This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AB66 Publication ID: Spring 2003 
Title: Food Labeling: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims 
Abstract: Section 403(q) of the Federal Food, Drug, and Cosmetic Act, which was added by the Nutrition Labeling and Education Act of 1990 (NLEA), requires that the label or labeling of food products bear nutrition information. Among other things, section 403(q) of the Act authorizes the Food and Drug Administration (FDA) to add or delete nutrients that are to be declared on the labels or labeling of food products by regulation if it finds such action necessary to assist consumers in maintaining healthy dietary practices. FDA issued final regulations implementing NLEA in 1993. FDA subsequently received a citizen petition requesting that FDA amend its regulations on food labeling to require that the amount of trans fatty acids be listed in the nutrition label and be limited wherever saturated fat limits are placed on nutrient content claims, health claims, or disqualifying levels and disclosure levels. In response to this petition and based on new evidence, FDA proposed the actions requested in the petition on November 17, 1999 (64 FR 62746). In addition, FDA proposed to define the claim "trans fat free." 
Agency: Department of Health and Human Services(HHS)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Yes  Unfunded Mandates: Private Sector 
CFR Citation: 21 CFR 101 
Legal Authority: 21 USC 321; 21 USC 331; 21 USC 342; 21 USC 343; 21 USC 348; 21 USC 371; ... 
Legal Deadline:  None

Statement of Need: FDA intends to publish a final rule amending its nutrition labeling regulations to incorporate requirements for trans fatty acids in labeling for several reasons. First, this final rule responds, in part, to a citizen petition on trans fatty acids in food labeling from the Center for Science in the Public Interest. Also, recent research shows that dietary trans fatty acids raise low density lipoprotein cholesterol (LDL-C), the major diet related risk factor for coronary heart disease (CHD). Finally, the information on trans fatty acids in nutrition labeling is needed to assist consumers in maintaining healthy dietary practices.

Summary of the Legal Basis: The NLEA (Pub. L. 101-535) amended the Federal Food, Drug, and Cosmetic Act (the Act) to provide, among other things, that certain nutrients and food components be included in nutrition labeling. Sections 403(q)(2)(A) and (q)(2)(B) of the Act provide the agency with authority to, by regulation, add or delete nutrients included in the food label or labeling if the agency finds that such action will assist consumers in maintaining healthy dietary practices.

Alternatives: FDA proposed, in the November 1999 proposal, that when trans fatty acids are present in a food, the declaration of saturated fat must bear a symbol that refers to a footnote at the bottom of the nutrition label that states the number of grams of trans fatty acids present in a serving of the product, i.e., "Includes ___ g trans fat." In addition to the proposed option, the agency considered a variety of other options for the declaration of trans fatty acids in the Nutrition Facts panel. The other options were: (1) include trans fatty acids with saturated fat and call the total value "saturated fat;" (2) include trans fatty acids with saturated fat and call the total value "saturated fat," and add an asterisk after the term "saturated fat" when the food contains trans fatty acids that refers to a footnote stating "Contains ____ g trans fat;" (3) include trans fatty acids with saturated fat and call the total value "saturated + trans fat;" and (4) list trans fatty acids separately under saturated fat.

Anticipated Costs and Benefits: FDA has estimated the benefits of the proposed rule in the range of $25 to $50 billion compared with costs in the range of $400 to $900 million (discounted at 7 percent for 20 years). The value of the benefits were estimated based on CHD morbidity and mortality prevented. The costs were estimated based on a formula that included costs for testing, decisionmaking, information panel reprinting, relabeling of the principal display panels, and product reformulation.

Risks: The American Heart Association estimates that CHD causes 1.1 million heart attack cases annually, with 33 percent of them fatal. FDA used these estimates as the baseline to estimate the number of cases and fatalities prevented by this rule. The agency estimated the rule would annually prevent 6,300 to 17,100 cases of CHD and 2,100 to 5,600 deaths, using three different methods to estimate these benefits. Thus, the labeling changes resulting from this rule are expected to reduce the risk of CHD, preventing, at a minimum, 6,300 cases of CHD and 2,100 deaths annually.

Timetable:
Action Date FR Cite
NPRM  11/17/1999  64 FR 62746 
NPRM Comment Period Reopened  12/05/2000  65 FR 75887 
NPRM Comment Period End  01/19/2001   
NPRM Comment Period Reopened  11/15/2002   
NPRM Comment Period End  12/16/2002   
Final Rule  06/00/2003   
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: Local, State, Tribal 
Small Entities Affected: Businesses  Federalism: Yes 
Included in the Regulatory Plan: Yes 
Agency Contact:
Julie Moss
Consumer Safety Officer
Department of Health and Human Services
Food and Drug Administration
(HFS-832), Center for Food Safety and Applied Nutrition (HFS-830), 5100 Paint Branch Parkway,
College Park, MD 20740
Phone:301 436-2373
Fax:301 436-2639
Email: julie.moss@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us